Loading stock…

Hansoh Pharmaceutical Group Company Limited (3692) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Hansoh Pharmaceutical Group Company Limited

3692Market cap $27BPrice $4.3

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Develops and sells prescription drugs across oncology, diabetes, and central nervous system disorders in China. One of the country's largest innovative drugmakers, it's pivoted from generics to cutting-edge biologics, striking billion-dollar licensing deals with global giants like Merck.

In Bastion Portfolios?

52W Return-7%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+16%8

Revenue Forecast

Rev CAGR (1y)+18%8

Rev CAGR (3y)+12%7

Rev CAGR (5y)+14%9

Earnings Forecast

EPS Growth Y+1+21%8

EPS Growth Y+2+4%5

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin37%9

Net Income Margin42%10

Free Cash Flow Margin32%9

Debt

Net Debt/EBITDA-5.210

Efficiency

ROE19%8

ROA16%10

Earnings Stability88

GEAR+VERY STRONG89

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)272

P/E Ratio (Forward 3y)242

P/BV4.73

EV Multiples

EV/EBITDA Fwd222

EV/EBIT Fwd233

Yield

Free Cash Flow Yield2.9%5

Dividend Yieldna–

Momentum

Short term

1 month return-4%6

3 month return+7%8

YTD return-3%4

Mid term

Price vs 52wHigh78%5

1 year return-9%3

Long term

3 year return+254%9

5 year return+95%7

Risk Shield

Price Risk

Beta0.85

Volatility41%4

Free Cash Flow

Free Cash Flow Margin32%9

Free Cash Flow Yield2.9%5

Quality

ROCE17%8

Earnings Stability88

Net Debt/EBITDA-5.210

02Growth

Is it actually growing, and how fast?

3692Hansoh Pharmaceutical Group Company

Revenue FY25$2.1B

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+18%8

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+14%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+21%8

EPS growth, FY27E+4%5

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 14%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 12%/yr).

WATCH

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 12%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

3692Hansoh Pharmaceutical Group Company

Total return Current37.6%

Price return Current30.8%

MOMENTUM RATING↗

AVERAGE64 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return+7%8

YTD return-3%4

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-9%3

3-year return+254%9

5-year return+95%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +254% over three years and +95% over five, ahead of 70% of the market.

Strong recent results. The stock is outperforming over three months (+7%).

WATCH

It's down 9% over the past year, now 22% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-4%) and so far this year (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Hansoh Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

3692Hansoh Pharmaceutical Group Company

Revenue FY25$2.1B

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+18%8

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+14%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+21%8

EPS growth, FY27E+4%5

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 14%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 12%/yr).

WATCH

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 12%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

3692Hansoh Pharmaceutical Group Company

Total return Current37.6%

Price return Current30.8%

MOMENTUM RATING↗

AVERAGE64 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return+7%8

YTD return-3%4

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-9%3

3-year return+254%9

5-year return+95%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +254% over three years and +95% over five, ahead of 70% of the market.

Strong recent results. The stock is outperforming over three months (+7%).

WATCH

It's down 9% over the past year, now 22% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-4%) and so far this year (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Hansoh Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community